A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy, Metabolic Dysfunction-associated Steatohepatitis
In brief
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following administration of single rising doses and administration of multiple rising doses.
Key facts
- Study ID
- NCT06575400
- Run by
- Boehringer Ingelheim
- People needed
- 124
- Starts
- 2024-09-12
- Expected to finish
- 2028-03-20
- Last updated by the study team
- 2026-07-07
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- SGS Life Science Services - Clinical Research — Edegem, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.